SCHEMBL14045705

SCHEMBL14045705

CN(Cc1ccccc1)CC1CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
BLM P54132 1/20 0.52
TSHR P16473 2/20 0.50
CARM1 Q86X55 1/20 0.50
PRMT6 Q96LA8 1/20 0.50
PRMT8 Q9NR22 1/20 0.50
USP2 O75604 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
PYCR1 P32322 1/20 0.48
AOC3 Q16853 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SLC18A3 Q16572 1/20 0.45
OPRM1 P35372 2/20 0.44
OPRD1 P41143 2/20 0.44
OPRK1 P41145 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8283980 0.93 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL4686478 0.91 CARM1 (0.47) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL522763 0.91 SLC18A3 (0.49) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL5651526 0.88 GBA1 (0.56) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL1191857 0.88 HTT (0.54) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL16327151 0.82 PYCR1 (0.50) PYCR1
SCHEMBL12685123 0.82 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL7768827 0.82 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL31716232 0.82 CARM1 (0.49) ALDH1A1LMNASMN1; SMN2BLMTSHR
SCHEMBL3377314 0.82 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2BLMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885LMNA 2811/4885SMN1; SMN2 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.